News Feed Item

Hologic Announces First Quarter Fiscal 2014 Operating Results

BEDFORD, Mass., Feb. 3, 2014 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced its results for the first fiscal quarter ended December 28, 2013.

Highlights of the Quarter Include:

  • Revenues of $612.4 million.
  • Non-GAAP net income of $94.1 million, or $0.34 per diluted share, and adjusted EBITDA (non-GAAP earnings before interest, taxes, depreciation and amortization) of $213.5 million.
  • Net loss of $5.4 million, or $0.02 per diluted share, calculated in accordance with U.S. generally accepted accounting principles (GAAP).
  • Stephen P. MacMillan named President and Chief Executive Officer, and a member of the Board of Directors.
  • FDA approval of the Aptima HPV 16 18/45 genotype assay for use on the Panther system.
  • Voluntary prepayment of an additional $100 million on the Term Loan B facility on October 31, 2013.
  • Redeemed in full $405 million of principal of the 2.00% Convertible Senior Notes issued in 2007.

The following non-GAAP financial measures are included in this press release: revenues, net income, earnings per diluted share (EPS), and adjusted EBITDA. The Company's definitions of these non-GAAP financial measures, and the reconciliations of these measures to the Company's comparable GAAP financial measures for the periods presented, are set forth in the supplemental information attached to this press release. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

First Quarter Fiscal 2014 Operating Results Overview:

First quarter fiscal 2014 revenues decreased 3.0% to $612.4 million from $631.4 million in the prior year (first quarter sales of the prior year included $12.6 million of revenues from Lifecodes, which the Company sold in March 2013). During the same period, non-GAAP revenues decreased 5.0% from $644.6 million. Non-GAAP revenues in the first quarter of fiscal 2013 reflect the addition of $13.3 million primarily related to contingent revenue earned and received under the Company's blood screening collaboration that was eliminated as a result of the effect of purchase accounting.

Fluctuation in foreign currency exchange rates had a negligible impact on revenues compared with the first quarter of fiscal 2013.

First quarter fiscal 2014 net loss was $5.4 million, or $0.02 per diluted share, compared with net income of $3.1 million, or $0.01 per diluted share, for the same period in the prior year. First quarter fiscal 2014 non-GAAP net income was $94.1 million, or $0.34 per diluted share, a decrease of 7.5% and 9.5%, respectively, compared to $101.8 million, or $0.38 per diluted share, in the prior year.

"While we delivered on our commitments in the quarter, we clearly have work to do to return to sustainable top and bottom line growth," said Stephen MacMillan, President and Chief Executive Officer. "Looking forward, I am energized by our unique collection of leading product technologies and a deeply committed and passionate employee base to drive organic growth. Through the balance of fiscal 2014, we will remain focused on improving our operating performance and growth profile and on paying down our debt balance, which we believe will enhance shareholder value."

First Quarter Fiscal 2014 Revenue Overview by Segment (Compared to the First Quarter Fiscal 2013):

  • Diagnostics revenues totaled $285.8 million compared to revenues of $305.9 million in the prior year, a decrease of 6.6%. On a non-GAAP basis, which includes the $13.3 million prior year adjustment described above, sales declined 10.5%. This decline was primarily due to: (i) the Company's divestiture of its Lifecodes business in March 2013, which generated revenues of $12.6 million in the prior year first quarter; (ii) decreases in ThinPrep pap test sales in the U.S. attributed to interval expansion, as well as lower average sales prices internationally; and (iii) a decrease in blood screening revenues, primarily resulting from lower West Nile Virus assay sales. Partially offsetting these declines were increases in molecular product sales from the Company's Aptima product line.
  • Breast Health revenues grew 2.6% to $226.5 million compared to $220.8 million in the prior year. This increase was driven primarily by: increased sales of 3D Dimensions systems as the Company continues to drive a sales shift to 3D Dimensions systems from its 2D systems; service revenue growth of $6.0 million, or 7.5%, from the growing installed base of digital mammography systems; and, to a lesser extent, biopsy device sales growth as a result of market share gains and growth in existing accounts. Partially offsetting these increases was the expected overall sales decline of 2D systems as customers move to the Company's 3D systems. 
  • GYN Surgical revenues totaled $78.9 million compared to $80.9 million in the prior year, a decrease of 2.5%. Significant growth in MyoSure system sales was offset by lower NovaSure system sales. 
  • Skeletal Health revenues totaled $21.3 million compared to $23.7 million in the prior year, a decrease of 10.1%, resulting from decreases in sales of bone densitometry and mini C-arm systems.

Financial Guidance:

The Company's guidance includes current operations, including revenues from its approved and cleared products. This guidance does not include the effects of any future stock repurchases, acquisitions, divestitures or additional voluntary debt payments that may occur during fiscal 2014.

Second Quarter Fiscal 2014 (Quarter Ending March 29, 2014):

  • The Company expects second quarter fiscal 2014 revenues of $605 million to $615 million. Year-over-year, this represents a decrease of 1% to 2% over second quarter fiscal 2013 non-GAAP revenues of $619.1 million (prior year reflects the addition of $6.4 million, primarily relating to a purchase accounting adjustment in the second quarter). The decrease is expected primarily from a decline in sales of ThinPrep pap tests and NovaSure systems, and the elimination of revenues from Lifecodes, which were $10.6 million in the second quarter of fiscal 2013. This decrease is expected to be partially offset by the continued ramp-up of new products including 3D Dimensions, molecular assays, and MyoSure systems.
  • The Company expects non-GAAP EPS of $0.32 to $0.34.

Fiscal 2014 (Year Ending September 27, 2014):

  • The Company is reaffirming fiscal 2014 revenue guidance of $2.425 billion to $2.475 billion. Year-over-year, this represents a decrease of 1% to 3% over fiscal 2013 non-GAAP revenues of $2.51 billion (prior year reflects the addition of $19.7 million primarily relating to a purchase accounting adjustment). The decrease is expected to be primarily a result of a decline in sales of ThinPrep pap tests, blood screening assays, and NovaSure systems, and the elimination of revenues from Lifecodes, which were $23 million in fiscal 2013. This decrease is expected to be partially offset by the continued ramp-up of new products including 3D Dimensions, molecular assays, and MyoSure systems.
  • The Company expects non-GAAP EPS of $1.34 to $1.38 (as compared to $1.32 to $1.38 provided on November 12, 2013). This includes an incremental reduction in EPS from the prior year of $0.02 from the impact of the medical device excise tax and $0.05 from an increase in the expected annual effective tax rate.

Hologic may not generate expected revenues and may incur expenses or charges, realize income or gains, or execute transactions in fiscal 2014 that could cause actual results to vary from the guidance above. In addition, the Company is continuing to monitor the effects of the U.S., European and general worldwide economic and regulatory conditions and related uncertainties, including the implementation of healthcare cost containment measures and healthcare reform legislation, as well as foreign currency fluctuations, which, along with other uncertainties facing the Company's business including those referenced elsewhere herein and its filings with the Securities and Exchange Commission, could adversely affect anticipated results.

Conference Call and Webcast:

Hologic's management will host a conference call on Monday, February 3, 2014, at 5:00 p.m. (Eastern) to discuss first quarter fiscal year 2014 operating results. Interested participants may listen to the call by dialing 877-397-0292 or 719-325-4942 for international callers and referencing code 6120983 approximately 15 minutes prior to the call. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through Friday, February 21, 2014, at 888-203-1112 or 719-457-0820 for international callers, access code 6120983. The Company will also provide a live webcast of the call. Interested participants may access the webcast on the Company's website at www.investors.hologic.com/investors-overview. A PowerPoint presentation related to the conference call will be posted to the site.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.

Hologic, Aptima, Dimensions, Gen-Probe, MyoSure, NovaSure, Panther, and ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer:

This News Release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information included herein based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company's strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company's business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ability of the Company to successfully manage recent and ongoing leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees; U.S., European and general worldwide economic conditions and related uncertainties; the Company's reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; uncertainties regarding the recently enacted or future healthcare reform legislation, including associated tax provisions, or budget reduction or other cost containment efforts; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company's products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including without limitation, the Company's ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, the risks that acquisitions may involve unexpected costs or unexpected liabilities, including the risks and challenges associated with the Company's recent acquisition of Gen-Probe and operations in China; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company's international activities and businesses; manufacturing risks, including the Company's reliance on a single or limited source of supply for key components, and the need to comply with especially high standards for the manufacture of many of its products; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company's products; the Company's leverage risks, including the Company's obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.

The risks included above are not exhaustive. Other factors that could adversely affect the company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.




(In thousands)

December 28, 2013

 September 28, 2013



Cash and cash equivalents

$                   448,637

$               829,404

Accounts receivable, net






Prepaid expenses and other current assets



Total current assets



Property and equipment, net



Intangible assets, net






Other assets



$                8,484,308

$            9,000,823



Current portion of long-term debt

$                     77,033

$               563,812

Accounts payable



Accrued expenses



Deferred revenue and other current liabilities



Total current liabilities



Long-term debt, net of current portion



Deferred income taxes and other long-term liabilities



Total long-term liabilities



Total stockholders' equity



$                8,484,308

$            9,000,823



(In thousands, except per share data)

Three Months Ended

December 28, 2013

December 29, 2012


Product sales

$                 512,382

$                 533,254

Service and other revenues






Cost of product sales



Cost of product sales – amortization of intangible assets



Cost of service and other revenues



Research and development



Selling and marketing



General and administrative



Amortization of intangible assets



Contingent consideration



Gain on sale of intellectual property



Restructuring and divestiture charges





Income from operations



Interest expense



Other income



Debt extinguishment loss



Loss before income taxes



Provision (benefit) for income taxes



Net (loss) income

$                   (5,351)

$                     3,118

Net (loss) income per common share:


$                      (0.02)

$                        0.01


$                      (0.02)

$                        0.01

Weighted average number of shares outstanding:







Explanatory Note:    

(1) Stock-based compensation included in costs and expenses during the three months ended December 28, 2013 was $1,510 for cost of revenues, $1,873 for research and development, $1,749 for selling and marketing, $3,833 for general and administrative and $4,761 for restructuring and divestiture. Stock-based compensation included in costs and expenses during the three months ended December 29, 2012 was $1,834 for cost of revenues, $1,868 for research and development, $2,201 for selling and marketing, $5,941 for general and administrative and $222 for restructuring and divestiture.


(In thousands, except earnings per share)

Three Months Ended

December 28, 2013

December 29, 2012


GAAP revenues

$                 612,448

$                  631,362

Adjustment primarily related to blood screening collaboration




Non-GAAP revenues

$                 612,448

$                  644,637


GAAP (loss) earnings per share - Diluted

$                      (0.02)

$                       0.01

Adjustment to net (loss) income (as detailed below)



Non-GAAP earnings per share – Diluted

$                        0.34


$                       0.38



GAAP net (loss) income 

$                     (5,351)

$                      3,118


Amortization of intangible assets





Contingent consideration




Non-cash interest expense relating to convertible notes





Acquisition and integration-related costs





Restructuring and divestiture charges





Fair value adjustment to depreciation expense





Debt extinguishment loss




Fair value write-up of acquired inventory sold




Contingent revenue primarily from blood screening collaboration




Gain on sale of intellectual property




Other charges (gains), net





Income tax effect of reconciling items





Non-GAAP net income

$                     94,148

$                 101,778


Non-GAAP net income

$                    94,148

$                 101,778

Interest expense, net, not adjusted above



Provision for income taxes



Depreciation expense, not adjusted above



Adjusted EBITDA

$                  213,534

$                 227,503

Explanatory Notes:             

(1) To primarily reflect a fair value adjustment relating to contingent revenue earned and received post acquisition under the Company's blood screening collaboration, which was eliminated under purchase accounting.

(2) Non-GAAP earnings per share was calculated based on 275,471 and 269,379 weighted average diluted shares outstanding for the three months ended December 28, 2013 and December 29, 2012, respectively.

(3) To reflect a non-cash charge attributable to the amortization of intangible assets.

(4) To reflect a charge to operating expenses attributable to contingent consideration related to certain of the Company's acquisitions.

(5) To reflect certain non-cash interest expense related to the Company's convertible notes.

(6) To reflect certain costs associated with the Company's acquisition(s) and integration plans, which primarily include retention costs, transfer costs, and asset impairments.

(7) To reflect restructuring and other divestiture charges.

(8) To reflect a non-cash fair value adjustment for additional depreciation expense related to the fair value write-up of fixed assets acquired from Gen-Probe.

(9) To reflect debt extinguishment costs associated with the Company's voluntary $100 million prepayment on the Term Loan B facility.

(10) To reflect a non-cash adjustment recorded for the fair value write-up of inventory acquired from Gen-Probe and sold during the reporting period.

(11) To reflect a net gain resulting from a cash payment received in final settlement of an agreement, net of costs associated with this transaction.

(12) To reflect the net impact from miscellaneous transactions during the period.

(13) To reflect an estimated annual effective tax rate of 34.5% for the three months ended December 28, 2013 and an annual effective tax rate of 32.0% for the three months ended December 29, 2012 on a non-GAAP basis.

Future Non-GAAP Adjustments:

Future GAAP EPS may be affected by changes in ongoing assumptions and judgments relating to the Company's acquired businesses, and may also be affected by nonrecurring, unusual or unanticipated charges, expenses or gains, all of which are excluded in the calculation of non-GAAP EPS as described in this press release. It is therefore not practicable to reconcile non-GAAP EPS guidance to the most comparable GAAP measure. 

Use of Non-GAAP Financial Measures:

The Company has presented the following non-GAAP financial measures in this press release: revenues; net income; EPS; and adjusted EBITDA. The Company defines its non-GAAP revenues to primarily include contingent revenue earned post-acquisition under the blood screening collaboration which was eliminated under purchase accounting. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines its non-GAAP net income and EPS to exclude: (i) the amortization of intangible assets; (ii) acquisition-related charges and effects, such as charges for contingent consideration, transaction costs, integration costs including retention, and credits and/or charges associated with the write-up of acquired inventory and fixed assets to fair value, and the effect of a reduction in revenue primarily related to contingent revenue under the blood screening collaboration, described above; (iii) non-cash interest expense related to amortization of the debt discount for convertible debt securities; (iv) restructuring and divestiture charges; (v) non-cash debt extinguishment losses and related transaction costs; (vi) litigation settlement charges (benefits); (vii) other-than-temporary impairment losses on investments; (viii) other one-time, nonrecurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (ix) income taxes related to such adjustments.

The Company believes the use of non-GAAP revenues is useful to investors as it eliminates certain effects of purchase accounting on its recognition of revenue. The Company believes the use of non-GAAP net income is useful to investors by eliminating certain of the more significant effects of its acquisitions and related activities, non-cash charges resulting from the application of GAAP to convertible debt instruments with cash settlement features, charges related to debt extinguishment losses, investment impairments, litigation settlements, and restructuring and divestiture initiatives. These non-GAAP measures also reflect how Hologic manages its businesses internally. In addition to the adjustments set forth in the calculation of the Company's non-GAAP net income and EPS, its adjusted EBITDA eliminates the effects of financing, income taxes and the accounting effects of capital spending. As with the items eliminated in its calculation of non-GAAP net income, these items may vary for different companies for reasons unrelated to the overall operating performance of a company's business. When analyzing the Company's operating performance, investors should not consider these non-GAAP financial measures as a substitute for net income prepared in accordance with GAAP.

Investor Relations and Media Contacts:

Deborah R. Gordon
Vice President, Investor Relations

(781) 999-7716

[email protected] 

Al Kildani
Senior Director, Investor Relations
(858) 410-8653
[email protected]


SOURCE Hologic, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Digital Transformation and Disruption, Amazon Style - What You Can Learn. Chris Kocher is a co-founder of Grey Heron, a management and strategic marketing consulting firm. He has 25+ years in both strategic and hands-on operating experience helping executives and investors build revenues and shareholder value. He has consulted with over 130 companies on innovating with new business models, product strategies and monetization. Chris has held management positions at HP and Symantec in addition to ...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve fu...
The standardization of container runtimes and images has sparked the creation of an almost overwhelming number of new open source projects that build on and otherwise work with these specifications. Of course, there's Kubernetes, which orchestrates and manages collections of containers. It was one of the first and best-known examples of projects that make containers truly useful for production use. However, more recently, the container ecosystem has truly exploded. A service mesh like Istio addr...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
As IoT continues to increase momentum, so does the associated risk. Secure Device Lifecycle Management (DLM) is ranked as one of the most important technology areas of IoT. Driving this trend is the realization that secure support for IoT devices provides companies the ability to deliver high-quality, reliable, secure offerings faster, create new revenue streams, and reduce support costs, all while building a competitive advantage in their markets. In this session, we will use customer use cases...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
DXWorldEXPO LLC announced today that "Miami Blockchain Event by FinTechEXPO" has announced that its Call for Papers is now open. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Financial enterprises in New York City, London, Singapore, and other world financial capitals are embracing a new generation of smart, automated FinTech that eliminates many cumbersome, slow, and expe...